Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS
Official title: Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis: A Targeted WGS Analysis
Funded at Univ of North Carolina Chapel Hill · NIH-11445429 · Data updated 2026-11-12
A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $233,250 |
| NIH project number | 1R21HL189039-01 |
| Project ID | NIH-11445429 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with cystic fibrosis who have or are eligible for highly effective modulator therapies and have existing whole-genome sequencing data available.
✕Less likely to help
Patients without CF or those not undergoing pharmacogenomic-guided therapy may not directly benefit from these findings.
What this research studies
This project analyzes WGS data from over 2,300 people with cystic fibrosis to create functionally defined pharmacogenomic scores. By concentrating on a targeted gene panel, the team aims to produce clearer, clinically actionable predictors of treatment responses. The approach could help clinicians tailor therapies based on a patient’s genetic makeup and improve understanding of drug-related outcomes beyond the drug itself. The study will translate complex sequencing data into practical scores that can be used in real-world CF care, leveraging existing patient data and collaborating labs.
Why it matters
Potential benefit: If successful, patients with CF could receive more personalized therapy decisions based on their genetic profile, potentially improving drug effectiveness and reducing adverse effects.
How similar studies have gone: Previous GWAS work has identified genetic factors in CF, and targeted pharmacogenomic approaches have shown promise in predicting drug responses in other diseases.
Where this research is happening
-
Univ of North Carolina Chapel Hill
Chapel Hill, United States Active
Researchers
- Principal investigator: Esther, Charles Richard — Univ of North Carolina Chapel Hill
- Study coordinator: Esther, Charles Richard
Related research
Other NIH-funded projects on the same topics.
-
Blocking CFTR in the cervix to prevent conception without hormones
A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.
-
Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy
A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.
-
Elastin-like particles to deliver gene therapies for cystic fibrosis
A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.
-
Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis
A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.
-
Gut microbiome in cystic fibrosis and colorectal cancer risk
Researchers are studying how the gut bacteria in adults with cystic fibrosis influence the development of colorectal cancer.
-
New peptide medicines to help cystic fibrosis–related diabetes
A small, patient-friendly study tests new peptide-based therapies aimed at improving insulin production and reducing pancreatic inflammation in people with CFRD.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.